EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 339 filers reported holding EXELIXIS INC in Q3 2021. The put-call ratio across all filers is 1.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,023,000 | -49.6% | 46,800 | -55.9% | 0.00% | -50.0% |
| Q2 2023 | $2,030,000 | -66.3% | 106,235 | -65.8% | 0.00% | -71.4% |
| Q1 2023 | $6,026,000 | +81.0% | 310,456 | +49.5% | 0.01% | +75.0% |
| Q4 2022 | $3,330,000 | -3.1% | 207,621 | -3.6% | 0.00% | 0.0% |
| Q3 2022 | $3,435,000 | -14.2% | 215,279 | +12.0% | 0.00% | 0.0% |
| Q2 2022 | $4,003,000 | +1663.4% | 192,231 | +1823.1% | 0.00% | – |
| Q1 2022 | $227,000 | +24.0% | 9,996 | 0.0% | 0.00% | – |
| Q4 2021 | $183,000 | -19.4% | 9,996 | -6.9% | 0.00% | – |
| Q3 2021 | $227,000 | +78.7% | 10,732 | +53.6% | 0.00% | – |
| Q2 2021 | $127,000 | -41.2% | 6,988 | -27.0% | 0.00% | – |
| Q1 2021 | $216,000 | -12.2% | 9,574 | -21.9% | 0.00% | – |
| Q4 2020 | $246,000 | -18.0% | 12,258 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $300,000 | +6.4% | 12,258 | +3.0% | 0.00% | – |
| Q2 2020 | $282,000 | +54.1% | 11,896 | +12.2% | 0.00% | – |
| Q1 2020 | $183,000 | -2.1% | 10,600 | 0.0% | 0.00% | – |
| Q4 2019 | $187,000 | 0.0% | 10,600 | 0.0% | 0.00% | – |
| Q3 2019 | $187,000 | -72.5% | 10,600 | -66.7% | 0.00% | – |
| Q2 2019 | $681,000 | -97.4% | 31,800 | -97.9% | 0.00% | -100.0% |
| Q3 2018 | $26,505,000 | -65.3% | 1,495,783 | -57.9% | 0.04% | -67.4% |
| Q2 2018 | $76,469,000 | +73.8% | 3,553,414 | +78.9% | 0.13% | +65.0% |
| Q1 2018 | $44,002,000 | -5.6% | 1,986,524 | +29.5% | 0.08% | -2.4% |
| Q4 2017 | $46,616,000 | +50.7% | 1,533,419 | +20.1% | 0.08% | +49.1% |
| Q3 2017 | $30,928,000 | +796.7% | 1,276,453 | +811.5% | 0.06% | +816.7% |
| Q2 2017 | $3,449,000 | +629.2% | 140,044 | +4.7% | 0.01% | +500.0% |
| Q1 2014 | $473,000 | -48.6% | 133,730 | -11.0% | 0.00% | -50.0% |
| Q4 2013 | $921,000 | +13.3% | 150,290 | +7.5% | 0.00% | 0.0% |
| Q3 2013 | $813,000 | +34.8% | 139,740 | +5.3% | 0.00% | +100.0% |
| Q2 2013 | $603,000 | – | 132,720 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |